FibroBiologics (Nasdaq: FBLG)

“Everything starts and ends with the science,” says Pete O’Heeron, CEO of FibroBiologics (Nasdaq: FBLG), on the importance of capital for advancing clinical trials. For FibroBiologics, this means preparing for clinical trials using spheroid-based fibroblasts to treat diabetic foot ulcers. Learn more about what’s ahead: https://bit.ly/4fdFCG6 #HealthInnovation #CellTherapy

FibroBiologics (Nasdaq: FBLG) announces encouraging results from our novel artificial thymus organoid program. Findings show organoids can persist and function for over 50 days after transplantation, with the ability to generate a range of mature T cells in animal models. This approach may support immune health in patients with age-related decline or after chemotherapy. For more: https://bit.ly/3YHS9vs #Immunotherapy #Biotech #Fibroblasts

FibroBiologics (Nasdaq: FBLG) will participate in two upcoming investor conferences where senior leadership will present and be available for one-on-one meetings. 2024 ThinkEquity LLC Conference on October 30 at 10:30 a.m. ET in New York: https://lnkd.in/eBN5YWUj BIO-Europe 2024 on November 5 at 1:30 p.m. CET in Stockholm, hosted by EBD Group: https://lnkd.in/dnuNZ2D #Biotech #Fibroblast #InvestorConferences

Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics (Nasdaq: FBLG), shares insights on the company’s latest patent filing, which focuses on generating three-dimensional organoids capable of producing various immune cells, including T cells, B cells, and potentially CAR-T cells. This innovative fibroblast-based technology has potential applications in treating immune deficiencies, speeding recovery post-chemotherapy, and improving CAR-T therapy by reducing adverse effects. https://lnkd.in/g_7gpkt5 #HealthInnovation #Immunotherapy #Chemotherapy

FibroBiologics (Nasdaq: FBLG) and Charles River Laboratories announced a collaboration to manufacture fibroblast cell-based therapies for chronic diseases. This working relationship is a pivotal step as FibroBiologics advances toward a significant wound care clinical trial in 2025 with CYWC628. For more: https://bit.ly/3BZ6jPT #Biotech #CellTherapy #FibroBlasts #DiabeticFootUlcer

FibroBiologics (Nasdaq: FBLG) is pleased to announce the issuance of a patent from the European Patent Office for our fibroblast-based approach to #cancer research. This patent covers methods that use modified fibroblasts to deliver tumor-inhibiting agents directly to cancer cells. For more: https://bit.ly/3zSyvDH #Patent #CancerResearch

FibroBiologics (Nasdaq: FBLG)' CEO, Pete O’Heeron, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, on Wednesday, October 16, 2024, at 10:00 a.m. ET. To attend, investors can register and watch the company discussion on the M-Vest page: https://bit.ly/4f4IODg Maxim Group LLC. #IR #InvestorConference

Research led by Dr. Hamid Khoja at FibroBiologics is potentially paving the way for new treatment avenues in multiple sclerosis (MS) using fibroblast cell therapy. Our team's work focuses on the immune modulation capabilities of fibroblasts, which play a role for bringing the dysregulated immune system of MS patients back to homeostasis. For more about our science, please visit https://bit.ly/3VVg7B0 #MedicalResearch #MultipleSclerosis #CellTherapy

We are proud to announce that Pete O’Heeron, CEO of FibroBiologics (Nasdaq: FBLG), has been named a finalist for CEO of the Year at the CPHI Pharma Awards. This recognition celebrates leaders who drive purposeful change within the pharma industry, and Pete’s commitment to advancing potential fibroblast-based therapies for chronic diseases exemplifies this spirit. For more: https://bit.ly/47XmFVc #CPHIPharmaAwards #LifeSciences #Leadership

#DidYouKnow at FibroBiologics (Nasdaq: FBLG), we aim to utilize fibroblasts not only for their role in forming connective tissue but also for their pivotal role in genetic studies and regenerative medicine? According to the National Human Genome Research Institute (NHGRI), fibroblasts are extracted through a simple skin biopsy. These versatile cells can be transformed into neurons or heart cells, aiding in disease research and the development of new therapies. For more, please visit https://bit.ly/4gRR2jT #DYK #HealthInnovation #CellTherapy